Novartis Reports Phase 3 Results for Iscalimab in Kidney Transplant Rejection Prevention

Novartis today announced results from the Phase 3 CIRRUS-1 trial evaluating iscalimab, an anti-CD40 monoclonal antibody, as part of a calcineurin inhibitor (CNI)-free immunosuppression regimen in kidney transplant recipients. The trial demonstrated that iscalimab-based regimens were non-inferior to CNI-based standard of care in preventing acute rejection.